Skip to main content
UniHealth

Doctor search

Kristen N Ganjoo, MD

Medical Oncology · Stanford

NPI 1669563391

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1
Since medical school
32 years
University of South Alabama College of Medicine, 1994

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ganjoo’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A85404 · Current

Licensed to practise in California · since 2003 · expires 2027-11-30 · University of Alabama School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Internal Medicine
  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$71,626

Medicare paid this office $71,626 for 205 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)88$34,182$170
Return visit (30+ min)104$20,108$123
Short return visit (20+ min)46$4,276$86
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$3,406$106
Long return visit (40+ min)15$2,878$131
See all 7 services
Every Original Medicare service billed
Long return visit (40+ min)88$34,182$170
Return visit (30+ min)104$20,108$123
Short return visit (20+ min)46$4,276$86
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$3,406$106
Long return visit (40+ min)15$2,878$131
New patient visit (60+ min)13$2,662$205
Return visit (30+ min)11$968$88

Who their Medicare patients are

205 Original Medicare patients in 2024. Average age 72 · Under 65 11% · 85 and older 7% · Women 57% · Also on Medicaid 23% · Health risk score 2.44. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 60% · Cancer 46% · Diabetes 26% · Chronic kidney disease 26% · Coronary heart disease 22% · Depression 20% · Atrial fibrillation 19% · Heart failure 16% · COPD 13% · Stroke 8% · Dementia 6%.

The office billed $389,960, Medicare allowed $90,878 and paid $71,626; for 524 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024205524722.44$389,960$71,626
2023233541732.22$325,417$54,190
2022247599732.32$348,781$56,865
2021241695722.26$397,200$68,333
2020199592722.20$248,832$42,318
2019205548712.08$88,450$42,887
2018237651712.15$80,704$48,791
2017246735712.44$172,892$58,681
2016245607701.90$136,075$45,169
2015244665701.92$176,826$54,567
2014280743702.03$223,712$65,831
2013186587691.85$133,343$39,365

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Original Medicare services billed in 2023
Long return visit (40+ min)87$20,109$130
Return visit (30+ min)110$13,860$84
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$6,098$109
Short return visit (20+ min)73$5,368$58
New patient visit (60+ min)23$3,841$167
New patient visit (45+ min)11$1,350$123
Telephone medical discussion with physician, 21-30 minutes11$1,096$84

2022: 9 services

Original Medicare services billed in 2022
Long return visit (40+ min)54$14,676$132
Return visit (30+ min)88$12,783$88
Short return visit (20+ min)100$8,213$57
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes38$7,797$91
New patient visit (60+ min)32$5,054$158
Initial hospital care with moderate level of medical decision making at least 75 minutes15$2,755$184
New patient visit (45+ min)16$1,764$110
Telephone medical discussion with physician, 21-30 minutes12$1,447$90
Hospital discharge day management, more than 30 minutes14$1,373$98

2021: 8 services

Original Medicare services billed in 2021
Long return visit (40+ min)64$17,919$134
Return visit (30+ min)83$14,155$90
Short return visit (20+ min)111$9,478$57
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes31$7,923$95
New patient visit (60+ min)40$6,755$169
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,701$185
Hospital discharge day management, more than 30 minutes26$2,727$101
New patient visit (45+ min)16$1,841$115

2020: 9 services

Original Medicare services billed in 2020
Short return visit (20+ min)114$8,361$45
Long return visit (40+ min)47$7,726$99
Return visit (30+ min)58$6,739$71
New patient visit (60+ min)22$3,183$145
Short return visit (20+ min)24$1,437$55
Hospital discharge day management, more than 30 minutes12$1,213$101
Return visit (30+ min)15$1,182$79
Telephone medical discussion with physician, 11-20 minutes13$765$48
Telehealth originating site facility fee13$277$21

2019: 7 services

Original Medicare services billed in 2019
Long return visit (40+ min)73$16,457$97
Return visit (30+ min)70$6,966$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$6,333$92
Short return visit (20+ min)94$5,897$43
New patient visit (60+ min)12$1,828$152
Hospital discharge day management, more than 30 minutes12$1,038$86
New patient visit (30+ min)11$652$59

2018: 6 services

Original Medicare services billed in 2018
Long return visit (40+ min)77$22,082$96
Short return visit (20+ min)103$8,570$43
Return visit (30+ min)82$7,309$64
New patient visit (45+ min)19$2,075$109
New patient visit (60+ min)13$1,957$151
New patient visit (30+ min)24$1,593$66

2017: 9 services

Original Medicare services billed in 2017
Long return visit (40+ min)64$15,812$98
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$10,715$90
Return visit (30+ min)83$9,169$65
Short return visit (20+ min)89$6,363$42
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,532$181
Hospital discharge day management, more than 30 minutes35$3,437$95
New patient visit (45+ min)24$2,772$116
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,958$63
New patient visit (30+ min)17$1,154$68

2016: 8 services

Original Medicare services billed in 2016
Return visit (30+ min)92$10,985$66
Long return visit (40+ min)48$7,634$95
Short return visit (20+ min)86$7,476$43
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$5,860$92
New patient visit (45+ min)37$4,222$114
New patient visit (60+ min)21$3,144$150
New patient visit (30+ min)22$1,492$68
Hospital discharge day management, more than 30 minutes14$1,361$97

2015: 9 services

Original Medicare services billed in 2015
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$12,118$93
Return visit (30+ min)88$10,920$66
Long return visit (40+ min)33$7,253$97
Initial hospital care with moderate level of medical decision making at least 75 minutes27$5,254$181
Short return visit (20+ min)86$5,052$40
New patient visit (60+ min)33$4,717$143
Hospital discharge day management, more than 30 minutes34$3,327$98
New patient visit (45+ min)24$2,701$113
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$1,556$65

2014: 9 services

Original Medicare services billed in 2014
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes75$17,836$92
Return visit (30+ min)101$10,253$63
Initial hospital care with moderate level of medical decision making at least 75 minutes56$10,228$179
Hospital discharge day management, more than 30 minutes71$6,946$96
Long return visit (40+ min)36$5,864$96
New patient visit (60+ min)35$5,004$143
Short return visit (20+ min)58$3,402$40
New patient visit (45+ min)19$2,197$116
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes18$2,050$64

2013: 8 services

Original Medicare services billed in 2013
Short return visit (20+ min)108$8,674$40
Return visit (30+ min)60$8,196$61
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$7,577$90
Initial hospital care with moderate level of medical decision making at least 75 minutes22$3,769$171
New patient visit (45+ min)28$3,163$113
New patient visit (60+ min)13$1,857$143
Hospital discharge day management, more than 30 minutes18$1,709$95
Long return visit (40+ min)16$1,677$76

Medicaid work

$2,236 in 2023

Medicaid paid $2,236 for 46 billed services this clinician did in 2023, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2023
Long return visit (40+ min)15$1,118
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES31$1,117
Medicaid work by year
202346215$2,236
202293216$5,613
202175215$4,379
202027113$822
See the largest Medicaid services in earlier years

2022

Largest Medicaid services in 2022
Long return visit (40+ min)47$3,088
Return visit (30+ min)46$2,525

2021

Largest Medicaid services in 2021
Return visit (30+ min)46$2,954
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES29$1,425

2020

Largest Medicaid services in 2020
Short return visit (20+ min)27$822

Drugs they prescribed that Part D paid

$1,595,318

Pharmacies billed $1,595,318 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 11% of their Part D prescriptions (75 of 681) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%. Long-acting opioids: 55% of their opioid prescriptions.

516 generic and fewer than 11 brand-name prescriptions · $1,595,318 in drug cost · 21 antibiotic prescriptions to 11 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Qinlock17$715,457$42,086
Lynparza16$221,032$13,814
Pazopanib11$65,316$5,938
Imatinib Mesylate24$31,705$1,321
Eliquis25$15,747$630
See all 19 drugs
Every Part D drug this clinician prescribed
Qinlock17$715,457$42,086
Lynparza16$221,032$13,814
Pazopanib11$65,316$5,938
Imatinib Mesylate24$31,705$1,321
Eliquis25$15,747$630
Xarelto15$12,571$838
Fentanyl19$1,140$60
Levothyroxine30$466$16
Pregabalin13$432$33
Escitalopram13$345$27
Oxycodone19$300$16
Gabapentin18$272$15
Methadone11$206$19
Prednisone34$159$5
Omeprazole15$149$10
Anastrozole16$137$9
Ondansetron20$100$5
Duloxetine11$89$8
Famotidine22$39$2

Year by year

Part D prescribing by year
20246819211% (75)None$1,595,318
20235269314% (71)None$1,434,476
20227301089% (68)None$1,743,951
202171210211% (81)None$2,215,535
20207029911% (80)None$823,678
20195481059% (47)21%$895,251
20184899011% (52)None$616,160
20174809812% (58)None$294,270
20163887014% (55)None$534,394
2015233599% (20)24%$330,257
20142907313% (37)None$249,684
2013250488% (20)None$424,644

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 13 drugs

Part D drugs prescribed in 2023
Qinlock15$601,572$40,105
Stivarga20$205,122$10,256
Imatinib Mesylate57$117,367$2,059
Xarelto20$13,905$695
Eliquis22$13,536$615
Gabapentin16$585$37
Methadone24$491$20
Pregabalin13$392$30
Oxycodone15$218$15
Prochlorperazine Maleate14$184$13
Hydrocodone-Acetaminophen13$175$13
Ondansetron20$171$9
Levothyroxine12$119$10

2022: 21 drugs

Part D drugs prescribed in 2022
Qinlock13$489,679$37,668
Pomalyst11$358,759$32,614
Ibrance21$314,822$14,992
Imatinib Mesylate28$84,597$3,021
Eliquis21$12,243$583
Xarelto11$6,396$581
Ondansetron Odt22$800$36
Gabapentin33$723$22
Ondansetron30$717$24
Omeprazole25$439$18
Oxycodone22$421$19
Prochlorperazine Maleate24$352$15
Fludrocortisone Acetate11$231$21
Pantoprazole19$214$11
Methadone13$204$16
Olanzapine13$198$15
Losartan15$189$13
Levothyroxine22$167$8
Prednisone25$145$6
Famotidine14$112$8
Furosemide13$16$1

2021: 19 drugs

Part D drugs prescribed in 2021
Qinlock17$581,866$34,227
Ibrance21$293,502$13,976
Sutent18$245,771$13,654
Xarelto11$6,313$574
Eliquis11$5,348$486
Imatinib Mesylate16$5,226$327
Pregabalin19$1,628$86
Ondansetron40$1,196$30
Gabapentin29$716$25
Oxycodone30$418$14
Omeprazole32$384$12
Dexamethasone13$319$25
Famotidine22$307$14
Prochlorperazine Maleate21$288$14
Escitalopram11$181$16
Prednisone20$156$8
Losartan14$85$6
Pantoprazole11$57$5
Lorazepam13$35$3

2020: 22 drugs

Part D drugs prescribed in 2020
Stivarga13$196,316$15,101
Votrient11$116,481$10,589
Retacrit11$20,248$1,841
Imatinib Mesylate29$13,550$467
Pregabalin18$1,396$78
Acyclovir18$1,063$59
Morphine Sulfate Er11$987$90
Lidocaine11$884$80
Ondansetron43$817$19
Sodium Chloride19$595$31
Diphenoxylate-Atropine12$520$43
Levothyroxine30$442$15
Oxycodone22$422$19
Gabapentin24$412$17
Anastrozole18$316$18
Famotidine16$228$14
Escitalopram12$173$14
Omeprazole22$173$8
Pantoprazole13$153$12
Zolpidem13$93$7
Prednisone14$67$5
Lorazepam11$31$3

2019: 14 drugs

Part D drugs prescribed in 2019
Votrient37$389,975$10,540
Imatinib Mesylate20$70,130$3,506
Ondansetron36$680$19
Lidocaine13$642$49
Levothyroxine15$345$23
Anastrozole21$307$15
Gabapentin19$286$15
Omeprazole15$194$13
Oxycodone11$185$17
Prednisone21$183$9
Prochlorperazine Maleate12$168$14
Pantoprazole19$149$8
Losartan12$120$10
Lorazepam15$89$6

2018: 11 drugs

Part D drugs prescribed in 2018
Votrient28$263,324$9,404
Imatinib Mesylate26$200,007$7,693
Xarelto11$7,221$656
Ondansetron35$999$29
Gabapentin23$356$15
Pantoprazole25$285$11
Prochlorperazine Maleate16$283$18
Oxycodone12$206$17
Omeprazole17$186$11
Prednisone22$171$8
Lorazepam15$97$6

2017: 10 drugs

Part D drugs prescribed in 2017
Imatinib Mesylate22$194,898$8,859
Ondansetron26$703$27
Oxycodone23$508$22
Gabapentin24$314$13
Prochlorperazine Maleate23$267$12
Omeprazole24$181$8
Anastrozole11$93$8
Lorazepam15$78$5
Prednisone15$75$5
Lisinopril13$23$2

2016: 9 drugs

Part D drugs prescribed in 2016
Imatinib Mesylate17$171,578$10,093
Votrient14$135,284$9,663
Ondansetron25$920$37
Gabapentin22$339$15
Tamoxifen Citrate11$275$25
Oxycodone11$267$24
Prochlorperazine Maleate19$224$12
Hydromorphone13$168$13
Omeprazole16$137$9

2015: 4 drugs

Part D drugs prescribed in 2015
Gleevec24$275,863$11,494
Ondansetron24$782$33
Gabapentin17$148$9
Lorazepam15$103$7

2014: 7 drugs

Part D drugs prescribed in 2014
Gleevec20$185,428$9,271
Hydrocodone-Acetaminophen15$890$59
Ondansetron19$626$33
Gabapentin29$261$9
Metoprolol12$203$17
Omeprazole11$100$9
Famotidine14$91$6

2013: 7 drugs

Part D drugs prescribed in 2013
Gleevec15$232,448$15,497
Afinitor13$102,909$7,916
Ondansetron13$720$55
Hydrocodone-Acetaminophen14$653$47
Gabapentin17$213$13
Potassium Chloride12$162$14
Amlodipine Besylate13$119$9

Money from drug and device companies

$2,960 in 2024

Industry payments by year
202411$2,960$2,960
2023210$6,171$7,836
202214$2,425$2,553
2020314$14,660$16,978
201915None$836

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Boehringer Ingelheim PharmaceuticalsNone$2,960
1 payment
  • Consulting · 2024-01-09 · $2,960
See the published payment
Every published payment
Boehringer Ingelheim PharmaceuticalsConsulting · 2024-01-09None$2,960
See earlier years (2023, 2022, 2020, 2019)

2023: $7,836

Payments by company in 2023
Deciphera PharmaceuticalsQinlock$5,326
7 payments
  • Consulting for Qinlock · 2023-12-07 · $3,746
  • Travel for Qinlock · 2023-10-25 · $1,227
  • Meals for Qinlock · 2023-10-24 · $25
  • Meals for Qinlock · 2023-10-24 · $26
  • Meals for Qinlock · 2023-10-24 · $23
  • Meals for Qinlock · 2023-10-24 · $1
  • Travel for Qinlock · 2023-10-24 · $278
Daiichi SankyoTuralio$2,510
3 payments
  • Consulting for Turalio · 2023-12-20 · $2,425
  • Meals for Turalio · 2023-11-01 · $51
  • Meals for Turalio · 2023-11-01 · $34

2022: $2,553

Payments by company in 2022
Daiichi SankyoTuralio$2,553
4 payments
  • Consulting for Turalio · 2022-12-16 · $2,425
  • Meals for Turalio · 2022-11-16 · $37
  • Meals for Turalio · 2022-11-16 · $69
  • Meals for Turalio · 2022-11-16 · $22

2020: $16,978

Payments by company in 2020
Daiichi SankyoTuralio$7,246
8 payments
  • Consulting for Turalio · 2020-03-05 · $6,110
  • Travel for Turalio · 2020-02-15 · $265
  • Travel for Turalio · 2020-02-15 · $332
  • Meals for Turalio · 2020-02-15 · $40
  • Meals for Turalio · 2020-02-15 · $40
  • Meals for Turalio · 2020-02-15 · $62
  • Meals for Turalio · 2020-02-15 · $88
  • Travel for Turalio · 2020-02-14 · $311
Foundation MedicineFoundationact$5,882
5 payments
  • Consulting for Foundationone Cdx · 2020-12-15 · $1,500
  • Meals for Foundationact · 2020-02-01 · $217
  • Travel for Foundationact · 2020-02-01 · $625
  • Travel for Foundationact · 2020-02-01 · $340
  • Consulting for Foundationact · 2020-02-01 · $3,200
Deciphera PharmaceuticalsQinlock$3,850
1 payment
  • Honoraria for Qinlock · 2020-12-24 · $3,850

2019: $836

Payments by company in 2019
Lilly USANone$836
5 payments
  • Travel · 2019-01-08 · $466
  • Travel · 2019-01-08 · $68
  • Travel · 2019-01-08 · $183
  • Travel · 2019-01-08 · $30
  • Travel · 2019-01-08 · $88

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2020Their institution$1,089,984
Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1/ Tsc2 Genes (Precision 1) · 2023Their institution$907,953
PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2023Their institution$337,642
Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes. · 2023Their institution$244,745
Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2024Their institution$242,624
PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2024Their institution$238,761
Merck Sharp & Dohme Corporation · A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934,V935 Htert Vaccination in Cancer Patients With Selected Solid Tumors · 2019Their institution$160,302
Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2023Their institution$129,078
PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2025Their institution$102,719
Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2025Their institution$94,714
GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2022Their institution$93,631
Karyopharm Therapeutics Inc. · Xpovio · 2020Their institution$90,576
Deciphera Pharmaceuticals Inc. · Intrigue A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib Intrigue · 2021Their institution$82,310
Aadi Bioscience, Inc. · Phase 2 Basket Trial of Nab-Sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in Tsc1tsc2 Genes Precision 1 · 2024Their institution$75,252
Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2021Their institution$67,804
Deciphera Pharmaceuticals Inc. · Intrigue A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib Intrigue · 2022Their institution$64,063
Karyopharm Therapeutics Inc. · A Phase 2-3 Multicenter, Randomized, Double-Blind Study of Selinexor (Kpt-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (Ddls) · 2021Their institution$45,769
Daiichi Sankyo Inc. · Turalio · 2019Their institution$43,831
Daiichi Sankyo Inc. · Pl3397-A-U126 · 2019Their institution$42,516
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2022Their institution$41,653
GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2021Their institution$39,014
Deciphera Pharmaceuticals Inc. · Study of Dcc-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2024Their institution$33,974
GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2024Their institution$32,567
Daiichi Sankyo Inc. · Pl3397-A-U126 · 2020Their institution$32,155
Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced Or Metastatic Soft Tissue Sarcoma · 2019Their institution$31,511
Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes · 2025Their institution$31,455
PTC Therapeutics, Inc. · A Phase 2/3 Study To Evaluate the Efficacy and Safety of Unesbulin in Unresectable Or Metastatic, Relapsed Or Refractory Leiomyosarcoma · 2022Their institution$30,109
GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2023Their institution$28,922
Aadi Bioscience, Inc. · A Phase 2 Multi-Center Open-Label Basket Trial of Nab-Sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in Tsc1 Or Tsc2 Genes. · 2022Their institution$28,655
GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2020Their institution$24,263
GlaxoSmithKline, LLC. · Long Term Follow-Up of Participants Exposed To Gsk3377794 (Ny-Eso-1c25 · 2022Their institution$23,430
Deciphera Pharmaceuticals Inc. · Intrigue A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib Intrigue · 2020Their institution$22,662
Daiichi Sankyo Inc. · Pl3397-A-U126 · 2021Their institution$22,042
Aadi Bioscience, Inc. · A Phase 2 Study of Abi-009 in Patients With Advanced Malignant Pecoma · 2022Their institution$21,943
Deciphera Pharmaceuticals Inc. · A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib (Intrigue) · 2023Their institution$20,894
Deciphera Pharmaceuticals Inc. · A Multicenter Phase 1/2, Open-Label Study of Dcc-3014 To Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor · 2022Their institution$19,779
Daiichi Sankyo Inc. · Turalio · 2022Their institution$18,160
Daiichi Sankyo Inc. · Turalio · 2020Their institution$15,554
E.R. Squibb & Sons, L.L.C. · Phase II Study of Ipilimumab Plus Nivolumab in Combination With Cryotherapy in Metastatic Or Locally Advanced Soft Tissue Sarcoma · 2023Their institution$15,000
GlaxoSmithKline, LLC. · Long Term Follow-Up of Participants Exposed To Gsk3377794 (Ny-Eso-1c25 · 2023Their institution$12,160
Deciphera Pharmaceuticals Inc. · A Study of Dcc-2618 Vs Sunitinib in Advanced Gist Patients After Treatment With Imatinib (Intrigue) · 2024Their institution$9,024
Adaptimmune LLC · Master Protocol To Assess the Safety and Antitumor Activity of Genetically Engineered Ny-Eso-1-Specific (C259) T Cells, Alone Or in Combination With Other Agents, in Hla-A2+ Participants With Ny-Eso-1 and/Or Lage-1a Positive Solid Tumors (Ignyte-Eso) · 2025Their institution$7,680
Daiichi Sankyo Inc. · Pl3397au126 · 2019Their institution$7,047
Deciphera Pharmaceuticals Inc. · A Safety Tolerability and Pk Study of Dcc-2618 in Patients With Advanced Malignancies · 2021Their institution$4,928
Daiichi Sankyo Inc. · Pl3397-A-U126 · 2022Their institution$4,510
Daiichi Sankyo Inc. · Turalio · 2021Their institution$3,968
Deciphera Pharmaceuticals Inc. · Invictus A Phase 3 Interventional Double-Blind Placebo-Controlled Study To Assess the Safety and Efficacy of Dcc-2618 in Patients With Advanced Gastrointestinal Stromal Tumors Who Have Received Treatment With Prior Anticancer Therapies · 2022Their institution$1,600
GlaxoSmithKline, LLC. · Master Protocol To Assess the Safety and Antitumor Activity of Genetic · 2019This clinician$1,155
Merck Sharp & Dohme Corporation · A Randomized, Open-Label, Phase 2 Trial of Cmb305 Sequentially Administered Lv305 and G305 and Atezolizumab in Patients With Locally Advanced, Relapsed, Or Metastatic Sarcoma Expressing Ny-Eso-1 · 2019Their institution$544

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1669563391
Licence
CA A85404California A85404: Current · expires 2027-11-30
Trained
University of South Alabama College of Medicine, 1994 · 32 years ago
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-09-27
NPI last updated
2024-04-29
NPI record certified
2024-04-29

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 875 Blake Wilbur Drive, Stanford, CA, 94305